NCT01891071

Brief Summary

Multiple sclerosis is a neurological disease that can affect lung function and cough efficacy. This pilot study will examine whether the lung volume recruitment technique can slow down the decline in lung function and cough.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
35

participants targeted

Target at P25-P50 for not_applicable multiple-sclerosis

Timeline
Completed

Started Jul 2013

Longer than P75 for not_applicable multiple-sclerosis

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 25, 2013

Completed
4 months until next milestone

Study Start

First participant enrolled

July 1, 2013

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 2, 2013

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2017

Completed
Last Updated

March 31, 2016

Status Verified

March 1, 2016

Enrollment Period

3.8 years

First QC Date

February 25, 2013

Last Update Submit

March 29, 2016

Conditions

Keywords

Multiple sclerosisLung volume recruitmentPulmonary function impairmentCough impairment

Outcome Measures

Primary Outcomes (1)

  • Rate of decline of FVC (forced vital capacity)

    up to 9 months

Secondary Outcomes (3)

  • Rate of decline of peak cough flow

    baseline, 2, 4, 6 and 9 months

  • Change from baseline in FVC at 2, 4, 6 and 9 months

    baseline vs 2, 4, 6 and 9 months

  • Change from baseline in peak cough flow at 2, 4, 6 and 9 months

    baseline vs 2, 4, 6 and 9 months

Study Arms (2)

Lung volume recruitment

EXPERIMENTAL

Lung volume recruitment twice daily for 9 months

Procedure: Lung volume recruitment

Standard care

NO INTERVENTION

Standard care

Interventions

Inflation of the lungs to their maximal insufflation capacity by the consecutive delivery, by a manual resuscitator in this study, of volumes of air that are held with a closed glottis

Also known as: Air stacking, Glossophayngeal breathing
Lung volume recruitment

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • History of multiple sclerosis, diagnosed by a neurologist in accordance with the 2010 McDonald criteria

You may not qualify if:

  • Concomitant parenchymal pulmonary disease or pleural disease
  • Symptomatic cardiomyopathy
  • Unable to perform pulmonary function testing or lung volume recruitment, due to comprehension or cooperation issues, physical inability such as bulbar or cerebellar dysfunction
  • Contra-indication to pulmonary function testing or lung volume recruitment such as myocardial infarction, bleeding aortic aneurysm, intracranial hemorrhage within the previous month
  • Known susceptibility to pneumothorax or pneumomediastinum
  • Not competent to provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

The Ottawa Hospital

Ottawa, Ontario, K1H 8L6, Canada

RECRUITING

Hôpital Charles-LeMoyne

Greenfield Park, Quebec, J4V2H1, Canada

RECRUITING

Related Publications (1)

  • Srour N, LeBlanc C, King J, McKim DA. Lung volume recruitment in multiple sclerosis. PLoS One. 2013;8(1):e56676. doi: 10.1371/journal.pone.0056676. Epub 2013 Jan 31.

    PMID: 23383293BACKGROUND

MeSH Terms

Conditions

Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Nadim Srour, MD, MSc

    Université de Sherbrooke

    STUDY CHAIR
  • Douglas A McKim, MD

    The Ottawa Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 25, 2013

First Posted

July 2, 2013

Study Start

July 1, 2013

Primary Completion

April 1, 2017

Study Completion

April 1, 2017

Last Updated

March 31, 2016

Record last verified: 2016-03

Locations